Promising results from the University of Pittsburgh APDA Center for Advanced Research Posted on October 24, 2019October 24, 2019 by Phil Franchina Promising results from the University of Pittsburgh APDA Center for Advanced Research Building off of pivotal APDA-funded work highlighted here, Dr. J. Timothy Greenamyre and his team, published a investigating the role of Leucine-rich Repeat Kinase (LRRK2) in the development of Parkinson’s disease (PD). LRRK2 is known to be mutated in a small percentage of […] Read More
Taking Parkinson’s education to the farmers market: educating under-served communities Posted on September 16, 2019September 16, 2019 by Phil Franchina Taking Parkinson’s education to the farmers market: educating under-served communities Dr. Lynda Nwabuobi, Movement Disorder Fellow at Columbia Presbyterian Medical Center in New York City, attended APDA’s Diversity in Parkinson’s Disease (PD) Research Conference in May and was inspired. Dr. Nwabuobi had just spent the day learning about health care disparities in PD care, low […] Read More
New medication, Istradefylline, gets approved for Parkinson’s disease Posted on September 4, 2019 by Stephanie Paul New medication, Istradefylline, gets approved for Parkinson’s disease On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval for Istradefylline, a new medication for Parkinson’s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA […] Read More
APDA Seed Funding Leads to Prestigious NIH Research Grant Posted on August 16, 2019August 16, 2019 by Stephanie Paul APDA Seed Funding Leads to Prestigious NIH Research Grant APDA is exceptionally proud to congratulate Dr. Beom-Chan Lee, APDA Research Grant awardee on receiving a recently-awarded National Institutes of Health (NIH) R21 grant. Read More
APDA-funded research finds new role for alpha-synuclein Posted on July 30, 2019July 31, 2019 by Stephanie Paul APDA-funded research finds new role for alpha-synuclein This new understanding of alpha-synuclein’s function could open up new ways of thinking about treatments for Parkinson’s disease. Read More
Merck announces its decision to stop the manufacturing of Sinemet CR Posted on July 17, 2019July 30, 2019 by Stephanie Paul Merck announces its decision to stop the manufacturing of Sinemet CR Merck has informed the Food and Drug Administration (FDA) that it will discontinue the manufacturing of Sinemet CR (controlled release). Read More
Bill Rasmussen, founder of ESPN, diagnosed with Parkinson’s disease Posted on July 15, 2019 by Stephanie Paul Bill Rasmussen, founder of ESPN, diagnosed with Parkinson’s disease Bill Rasmussen, founder of ESPN, shares his Parkinson’s disease diagnoses. Read More
$52 billion per year is spent on PD-related expenses, according to results of the Economic Burden of Parkinson’s Disease Study Posted on June 13, 2019June 14, 2019 by Dr. Rebecca Gilbert $52 billion per year is spent on PD-related expenses, according to results of the Economic Burden of Parkinson’s Disease Study In October 2018, APDA asked our constituents to consider participating in a new study called The Economic Burden of Parkinson’s Disease (PD), with the goal of estimating the economic burden of PD in the United […] Read More
Recently published results of a GDNF intraputaminal infusion clinical trial Posted on March 5, 2019 by Phil Franchina A clinical trial, is by definition an experiment or a test — an effort to determine if something works, or doesn’t. Sometimes, although the intended outcome of a clinical trial may fall short of expectations, the results are nevertheless intriguing and may spark additional avenues of investigation. Such is the case in a clinical trial […] Read More
FDA Approves Inbrija™ (levodopa inhalation powder) Parkinson’s disease Posted on December 23, 2018December 26, 2018 by Stephanie Paul FDA Approves Inbrija™ (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJA™ (levodopa inhalation powder) for the treatment of OFF periods in people with Parkinson’s disease (PD) taking carbidopa/levodopa. INBRIJA™ is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […] Read More
